营收提振业绩 美诺华2025年净利润同比预增49.69%到84.11%

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. (referred to as "Meinuo") expects a significant increase in its 2025 annual performance, with net profit projected to reach between 100 million to 123 million yuan, representing a year-on-year increase of 49.69% to 84.11% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company for 2025 to be between 100 million to 123 million yuan, which is an increase of 49.69% to 84.11% year-on-year [1] - The net profit after deducting non-recurring gains and losses is expected to be between 80 million to 95 million yuan, reflecting a year-on-year growth of 62.43% to 92.88% [1] Business Strategy - Meinuo's performance growth is primarily driven by an increase in operating revenue for 2025 [1] - The company adheres to a vertical integration strategy covering "pharmaceutical intermediates, raw materials, and formulations," serving major global markets and focusing on key therapeutic areas such as cardiovascular, central nervous system, antiviral, blood sugar reduction, and gastrointestinal treatments [1] - In 2025, Meinuo aims to leverage capital markets for "intrinsic growth + external expansion" to drive development, reinforcing its core business in specialty raw materials while expanding into upstream intermediate business and downstream formulation business [1] - The company is committed to continuous R&D innovation and business development, enhancing its integrated strategy and advancing the development and commercialization of cutting-edge pharmaceutical products [1]